# Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics

> **NCT01357876** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 8 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **OTHER:** Metformin

## Key facts

- **NCT ID:** NCT01357876
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-01
- **Primary completion:** 2011-07-07
- **Final completion:** 2011-07-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01357876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01357876, "Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01357876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*